14,15-epoxy-5,8,11-eicosatrienoic acid has been researched along with Cardiac Hypertrophy in 4 studies
14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, it is important to examine whether fenofibrate would modulate the cardiac P450 and its associated arachidonic acid metabolites and whether this modulation protects against isoproterenol-induced cardiac hypertrophy." | 7.80 | Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. ( Althurwi, HN; El-Kadi, AO; Elshenawy, OH, 2014) |
| " Therefore, it is important to examine whether fenofibrate would modulate the cardiac P450 and its associated arachidonic acid metabolites and whether this modulation protects against isoproterenol-induced cardiac hypertrophy." | 3.80 | Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. ( Althurwi, HN; El-Kadi, AO; Elshenawy, OH, 2014) |
| "Diabetic cardiac hypertrophy was developed by high-fat diet feeding combined with streptozotocin (40 mg/kg/d for 5 days, i." | 1.72 | 14,15-EET involved in the development of diabetic cardiac hypertrophy mediated by PPARs. ( Ding, S; Jiang, C; Jiang, Q; Qiu, H; Wu, K; Yang, C; Yang, J; Zhang, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 1 |
| Yang, C | 1 |
| Qiu, H | 1 |
| Yang, J | 1 |
| Wu, K | 1 |
| Ding, S | 1 |
| Jiang, C | 1 |
| Jiang, Q | 1 |
| Wang, X | 1 |
| Ni, L | 1 |
| Yang, L | 1 |
| Duan, Q | 1 |
| Chen, C | 1 |
| Edin, ML | 1 |
| Zeldin, DC | 1 |
| Wang, DW | 1 |
| Althurwi, HN | 1 |
| Elshenawy, OH | 2 |
| El-Kadi, AO | 2 |
| Amara, IE | 1 |
| Abdelrady, M | 1 |
4 other studies available for 14,15-epoxy-5,8,11-eicosatrienoic acid and Cardiac Hypertrophy
| Article | Year |
|---|---|
14,15-EET involved in the development of diabetic cardiac hypertrophy mediated by PPARs.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Cardiomegaly; Diabetes Mellitus; Diabetic Cardiomyopathies; Gl | 2022 |
CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Apoptosis; Calcium; Cardiomegaly; Cell Line; Cytochrome P-450 | 2014 |
Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Cardiomegaly; Cytochrome P-450 CYP2J2; Cytoc | 2014 |
Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Atrial Natriuretic Factor; Biomarkers; Cardi | 2014 |